Significance of serum thymidine kinase in prediction of the response to therapy in pa-tients with chronic lymphocytic leukemia

The prognostic value of serum thymidine kinase was evaluated in 230 patients with chronic lymphocytic leukemia under different types of modern therapy. Thymidine kinase activity in serum was assessed using radioenzyme methods. It is found that the efficiency of the treatment of patients with chronic lymphocytic leukemia using different chemotherapy and immunochemotherapy’s programs correlates with the content of thymidine kinase in serum. It was demonstrated that the combination of immunochemotherapy RFC eliminates the negative effect of thymidine kinase as a tumor marker from the direct effect of the treatment and the duration of response. The determination of thymidine kinase in the serum among patients with chronic lymphocytic leukemia can be recommended not only as an additional predictor of the disease and response to the therapy, but also for the selection of adequate treatment programs.

1. Clinical oncohematology. Ed. M.A. Volkova. Moscow: Meditsina, 2007. 1120 р. (in Russian)

2. Chen Y., Ying M., Chen Y. et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1.247 cancer patients in routine clinical settings // Int. J. Clin. Oncol. 2010. 15. (4). 359–368.

3. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells // Best Pract. Res. Clin. Haematol. 2007. 20. 399–413.

4. Goryainova N., Tretyak N., Kyselova O., Miro­nova O. Prognosis of induction hemotherapy results to thymidine kinase content in blood serum at diagnosis in the patients with acute myeloid leukemia // Ann. Hematol. 2006. 85. (1). 22–23.

5. Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines // Blood. 2008. 111. (12). 5446–5456.

6. Hallek M., Pflug N. State of the art treatment of chronic lymphocytic leukaemia // Blood Rev. 2011. 25. 1–9.

7. He E., Xu X.H., Guan H. et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin’s lymphoma // Nucleosides Nucleotides Nucleic Acids. 2010. 29. (4–6). 352–358.

8. Moreno C., Montserrat E. New prognostic mar­kers in chronic lymphocytic leukemia // Blood Rev. 2008. 22. (4). 211–219.

9. Pan Z.L., Ji X.Y., Shi Y.M. et al. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients // J. Cancer Res. Clin. Oncol. 2010. 136. (8). 1193–1199.

10. Von Euler H., Eriksson S. Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases // Vet. Comp. Oncol. 2011. 9. (1). 1–15.

11. Xu W., Shen Q.D., Yu H. et al. Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors // Zhonghua Xue Ye Xue Za Zhi. 2009. 30. (1). 8–12.